Qianmeng Lin

NHC Key Laboratory Of Cancer Proteomics
Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Journal: Journal of medicinal chemistry

Published: January 06, 2026

Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.

Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.

Journal: Communications biology

Published: August 08, 2024

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Journal: Journal of medicinal chemistry

Published: February 13, 2024

Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.

Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.

Journal: Toxicology and applied pharmacology

Published: January 21, 2024

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.

Journal: European journal of medicinal chemistry

Published: January 21, 2024

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.

Journal: iScience

Published: September 27, 2023

Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.

Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.

Journal: Communications chemistry

Published: June 24, 2023

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Journal: Journal of medicinal chemistry

Published: November 10, 2022

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects.

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects.

Journal: European journal of medicinal chemistry

Published: March 23, 2022

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

Journal: Journal of medicinal chemistry

Published: March 10, 2022

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.

Journal: Communications chemistry

Published: January 20, 2022

Upper Limb Lymphedema Impacts the Risk of Peripherally Inserted Central Catheter-Related Thrombosis in Patients with Breast Cancer.

Upper Limb Lymphedema Impacts the Risk of Peripherally Inserted Central Catheter-Related Thrombosis in Patients with Breast Cancer.

Journal: Lymphology

Published: January 01, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026